| Immune-related adverse events with immune checkpoint blockade: a comprehensive review JM Michot, C Bigenwald, S Champiat, M Collins, F Carbonnel, ... European journal of cancer 54, 139-148, 2016 | 2056 | 2016 |
| Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1 S Champiat, L Dercle, S Ammari, C Massard, A Hollebecque, ... Clinical Cancer Research 23 (8), 1920-1928, 2017 | 1204 | 2017 |
| High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial C Massard, S Michiels, C Ferté, MC Le Deley, L Lacroix, A Hollebecque, ... Cancer discovery 7 (6), 586-595, 2017 | 660 | 2017 |
| Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial AT Shaw, E Felip, TM Bauer, B Besse, A Navarro, S Postel-Vinay, ... The Lancet Oncology 18 (12), 1590-1599, 2017 | 647 | 2017 |
| Targeting FGFR signaling in cancer M Touat, E Ileana, S Postel-Vinay, F André, JC Soria Clinical cancer research 21 (12), 2684-2694, 2015 | 509 | 2015 |
| Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort … D Olmos, S Postel-Vinay, LR Molife, SH Okuno, SM Schuetze, ... The lancet oncology 11 (2), 129-135, 2010 | 384 | 2010 |
| Rationale for anti-OX40 cancer immunotherapy S Aspeslagh, S Postel-Vinay, S Rusakiewicz, JC Soria, L Zitvogel, ... European Journal of Cancer 52, 50-66, 2016 | 348 | 2016 |
| Combining epigenetic drugs with other therapies for solid tumours—past lessons and future promise D Morel, D Jeffery, S Aspeslagh, G Almouzni, S Postel-Vinay Nature Reviews Clinical Oncology 17 (2), 91-107, 2020 | 328 | 2020 |
| Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study SM Domchek, S Postel-Vinay, SA Im, YH Park, JP Delord, A Italiano, ... The Lancet Oncology 21 (9), 1155-1164, 2020 | 327 | 2020 |
| PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer RM Chabanon, G Muirhead, DB Krastev, J Adam, D Morel, M Garrido, ... The Journal of clinical investigation 129 (3), 1211-1228, 2019 | 276 | 2019 |
| Mutational landscape and sensitivity to immune checkpoint blockers RM Chabanon, M Pedrero, C Lefebvre, A Marabelle, JC Soria, ... Clinical Cancer Research 22 (17), 4309-4321, 2016 | 216 | 2016 |
| Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma S Postel-Vinay, AS Véron, F Tirode, G Pierron, S Reynaud, H Kovar, ... Nature genetics 44 (3), 323-327, 2012 | 207 | 2012 |
| Targeting the DNA damage response in immuno-oncology: developments and opportunities RM Chabanon, M Rouanne, CJ Lord, JC Soria, P Pasero, S Postel-Vinay Nature Reviews Cancer 21 (11), 701-717, 2021 | 163 | 2021 |
| Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score) F Bigot, E Castanon, C Baldini, A Hollebecque, A Carmona, ... European Journal of Cancer 84, 212-218, 2017 | 160 | 2017 |
| Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities S Postel-Vinay, C Gomez-Roca, LR Molife, B Anghan, A Levy, I Judson, ... J Clin Oncol 29 (13), 1728-1735, 2011 | 145 | 2011 |
| Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape KA Olaussen, S Postel-Vinay Annals of Oncology 27 (11), 2004-2016, 2016 | 142 | 2016 |
| The potential of exploiting DNA-repair defects for optimizing lung cancer treatment S Postel-Vinay, E Vanhecke, KA Olaussen, CJ Lord, A Ashworth, JC Soria Nature reviews Clinical oncology 9 (3), 144-155, 2012 | 140 | 2012 |
| Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) young oncologists committee burnout survey S Banerjee, R Califano, J Corral, E de Azambuja, L De Mattos-Arruda, ... Annals of Oncology 28 (7), 1590-1596, 2017 | 134 | 2017 |
| Long-term survival in patients responding to anti–PD-1/PD-L1 therapy and disease outcome upon treatment discontinuation ML Gauci, E Lanoy, S Champiat, C Caramella, S Ammari, S Aspeslagh, ... Clinical Cancer Research 25 (3), 946-956, 2019 | 125 | 2019 |
| Circulating cell-free tumor DNA analysis of 50 genes by next-generation sequencing in the prospective MOSCATO trial C Jovelet, E Ileana, MC Le Deley, N Motté, S Rosellini, A Romero, ... Clinical Cancer Research 22 (12), 2960-2968, 2016 | 122 | 2016 |
